Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
What’s the outlook for ASX Cannabis shares in 2022?
Here’s why the Creso Pharma (ASX:CPH) share price is surging 6% today
Why is the Creso Pharma (ASX:CPH) share price frozen today?
Why Creso Pharma, Hansen, Life360, and Serko shares are falling
Creso Pharma (ASX:CPH) share price down 7% as chair stands aside amid ASIC probe
Why the Creso Pharma (ASX:CPH) share price is down 29% this week
Creso Pharma (ASX:CPH) share price down 6% after speeding ticket
Why the Creso Pharma (ASX:CPH) share price fell 9% before freezing
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Creso Pharma Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its product portfolio includes Creso Animal Health products, Nutraceutical products, Topical products, Therapeutics products, and Lifestyle products. The company has operations in Switzerland, Canada, Colombia, Israel, and Australia. The company derives prime revenue from the Europe and Middle East regions.
|12 Aug 2022||$0.04||$0.00||0.00%||4,296,227||$0.04||$0.04||$0.04|
|11 Aug 2022||$0.04||$0.00||0.00%||2,125,437||$0.04||$0.04||$0.04|
|10 Aug 2022||$0.04||$0.00||0.00%||2,744,918||$0.04||$0.04||$0.04|
|09 Aug 2022||$0.04||$0.00||0.00%||9,090,335||$0.04||$0.04||$0.04|
|08 Aug 2022||$0.04||$0.00||0.00%||9,999,262||$0.04||$0.04||$0.04|
|05 Aug 2022||$0.04||$0.00||0.00%||16,003,840||$0.04||$0.04||$0.04|
|04 Aug 2022||$0.04||$-0.01||-20.41%||8,650,575||$0.04||$0.04||$0.04|
|26 Jul 2022||$0.05||$0.00||0.00%||1,919,922||$0.05||$0.05||$0.05|
|25 Jul 2022||$0.05||$0.00||0.00%||3,318,227||$0.05||$0.05||$0.05|
|22 Jul 2022||$0.05||$0.00||0.00%||4,288,369||$0.05||$0.05||$0.05|
|21 Jul 2022||$0.05||$0.00||0.00%||7,223,093||$0.05||$0.05||$0.05|
|20 Jul 2022||$0.05||$0.00||0.00%||1,793,501||$0.05||$0.05||$0.05|
|19 Jul 2022||$0.05||$0.00||0.00%||2,252,845||$0.05||$0.05||$0.05|
|18 Jul 2022||$0.05||$0.00||0.00%||4,291,390||$0.05||$0.05||$0.04|
|15 Jul 2022||$0.04||$0.00||0.00%||2,601,325||$0.04||$0.05||$0.04|
|27 Jul 2022||Boaz Wachtel||Expiry||1||$78,400||
As advised by the company. Expiry of Performance Rights.
|02 Nov 2021||Adam Blumenthal||Issued||37||$4,925,502||
Issue of options. As per announcement on 08/11/2021
|02 Nov 2021||James Ellingford||Issued||384||$49,941||
Issue of options. As per announcement on 08/11/2021
|02 Nov 2021||Boaz Wachtel||Issued||2||$381,333||
Issue of options. As per announcement on 08/11/2021.
|Mr Adam Blumenthal||Non-Executive DirectorNon-Executive Chairman||Nov 2015||
Mr Blumenthal has over 11 years' experience in Investment Banking and Corporate Finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of unlisted and listed companies. Adam has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries, using his experience and network of international contacts to provide corporate advisory and capital markets input. He has successfully brought to market several Medical Marijuana companies spanning Israel, Canada, Switzerland and Australia. He has also been actively involved in the Mining, Cyber Security, Health Care and IT sectors. He is a director of EverBlu Capital Pty Ltd, the Company's appointed corporate advisor and lead manager to the various capital raisings undertaken by the Company in CY2021. Outside of his formal business activities, Adam has lectured at a leading Sydney University covering corporate governance, corporate social responsibility and ASX listings - both at an undergraduate and postgraduate level. He is a supporter of Israeli innovation and has previously lived in Israel. He is a member of the Israel Business Club Sydney (IBCS).
|Dr James Anthony Ellingford||Executive Director||Nov 2015||
Dr Ellingford's professional life culminated in being President of an international publicly listed billion-dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.
|Mr Boaz Wachtel||Non-Executive Director||Nov 2015||
Mr Wachtel was Co-Founder and former Managing Director of MMJ-PhytoTech Ltd, Australia's first publicly traded Medical Cannabis Company. Co-founder of IMCPC - International Medical Cannabis Patient Coalition. He is an Israeli medical cannabis pioneer/activist, who formulated and assisted the Ministry of Health with the implementation of the National Medical Cannabis Program - one of only few national programs in the world. He is a frequent lecturer and adviser to governments, national committees, business and NGO's on medical cannabis program formulation, grow operations, international laws and UN drug convention compliance, as well as the founder (1999) and former Chairman of the Green Leaf Party, an Israeli political party for cannabis legalisation/medicalisation, human rights and ecology. Mr Wachtel is a certified clinical research manager and holds an MA in Management and Marketing from the University of Maryland.
|Mr Bruce Andrew Linton||Non-Executive Director||Jan 2022||
Mr Linton is a cannabis executive and has sector experience as a founder, CEO, Board member and advisor to a number of global cannabis and psychedelic focused companies. Mr Linton's experience include his role as founder, Chairman and ex-CEO of Canopy Group Corporation. Mr Linton was also responsible for securing market support for 16 funding rounds and progressing over 30 M&A opportunities. He led Canopy Growth through its start-up phase to becoming the first producing cannabis company to list on the New York Stock Exchange. Following his departure from Canopy Growth, he has led direct investments into the cannabis and psychedelic sector while undertaking management and strategic advisory roles. These include being Executive Chairman of Gage Cannabis Co. and a Director of psychedelic medicines company, Mind Medicines Inc.
|Mr William Lay||Chief Executive OfficerManaging Director||Jan 2022||
Mr Lay is an experienced cannabis executive and previously served as Executive Vice President - Strategy, Origination & Operations at Creso Pharma (refer ASX announcement: 6 September 2021). Mr Lay began his career with Canadian full service financial investment bank, BMO Capital Markets through roles across Canada and London. Shortly after his time with BMO Capital Markets, Mr Lay joined Canopy Growth Corporation (TSE: WEED, NASDAQ: CGC) as an M&A Associate, before being promoted to Associate Director, M&A, in 2019. In this role, he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group. Over the last four years, Mr Lay has managed and supported cannabis M&A transactions, including managing the acquisition in the history of the cannabis sector.
|Mrs Micheline MacKay||Executive Director||Jan 2022||
Mrs MacKay has 22 years of experience in regulatory environments, including pharmaceuticals, medical devices, and government regulated industries. She has held leadership positions for many years in different areas with a focus on business improvements and product development from laboratory scale to commercial operations. Mrs MacKay is currently the Corporate Manager of Creso Pharma's wholly owned Canadian subsidiary, Mernova Medicinal Inc. (Mernova). She has been in the position for nearly three years and is responsible for multiple functions including HR, quality assurance, and regulatory affairs. Mrs MacKay is the Health Canada designated Responsible Person in Charge at Mernova. She has practical experience in managing a business through specified key performance indicators, managing budgets, conducting regular audits and performance management.
|Mr Winton William Willesee||Joint Company Secretary||Oct 2018||
|Ms Erlyn Dale||Joint Company Secretary||Oct 2018||
|Mr Chris Grundy||Chief Financial Officer||
|Winton William Willesee||Joint Company Secretary||
|Erlyn Dale||Joint Company Secretary||
|Atlantic Capital Holdings Pty <Atlantic Capital A/C>||100,415,432||8.18%|
|Jamber Investments Pty Ltd <The Amber Schwarz Fam A/C>||50,392,066||4.10%|
|Mr Tyson Scholz||35,524,240||2.89%|
|Mr Bill Fleming <Fleming Family 2011 A/C>||30,568,312||2.49%|
|Bnp Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C>||29,201,889||2.38%|
|Suburban Holdings Pty Ltd <The Suburban Super Fund A/C>||28,279,263||2.30%|
|Citicorp Nominees Pty Limited||19,440,848||1.58%|
|Hsbc Custody Nominees (Australia) Limited||15,551,767||1.27%|
|Atlantic Capital Holdings Pty Ltd <Atlantic Capital A/C>||13,250,000||1.08%|
|Brispot Nominees Pty Ltd <House Head Nominee A/C>||8,873,683||0.72%|
|International Water & Energy Savers Ltd||8,800,000||0.72%|
|Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||6,972,451||0.57%|
|Mr John Langley Hancock||6,440,068||0.52%|
|Superhero Nominees Pty Ltd <Client A/C>||5,660,132||0.46%|
|Noble House Consulting Ltd||5,000,000||0.41%|
|Mr Kenneth Joseph Hall <Hall Park A/C>||5,000,000||0.41%|
|Mr Niall Buckley||4,680,256||0.38%|
|Mr Tyson Scholz I||4,500,000||0.37%|
|Mr Mitchel Fleming||4,399,440||0.36%|
|Mr Matthew Clarke Mallet||3,400,000||0.28%|
|Bnp Paribas Nominees Pty Ltd Acf Clearstream||3,031,955||0.25%|